ContraFect Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wir verfügen derzeit nicht über ausreichende Analystenabdeckung, um Wachstum und Umsatz für ContraFect zu prognostizieren.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	09 Nov 2023

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

Mar 09

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

Jan 15

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Nov 24

Contrafect EPS beats by $0.16

Nov 13

Gewinn- und Umsatzwachstumsprognosen

OTCPK:CFRX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2025	N/A	N/A	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
12/31/2023	N/A	N/A	N/A	N/A	1
9/30/2023	N/A	-24	-36	-36	N/A
6/30/2023	N/A	-36	-37	-37	N/A
3/31/2023	N/A	-46	-43	-43	N/A
12/31/2022	N/A	-65	-46	-46	N/A
9/30/2022	N/A	-60	-45	-45	N/A
6/30/2022	N/A	-48	-46	-46	N/A
3/31/2022	N/A	-35	-44	-44	N/A
12/31/2021	N/A	-20	-41	-41	N/A
9/30/2021	N/A	-22	-40	-40	N/A
6/30/2021	N/A	-14	-37	-37	N/A
3/31/2021	N/A	-26	-35	-35	N/A
12/31/2020	N/A	-28	-33	-33	N/A
9/30/2020	N/A	-32	-33	-33	N/A
6/30/2020	N/A	-41	-29	-29	N/A
3/31/2020	N/A	-32	-28	-28	N/A
12/31/2019	N/A	-13	-27	-27	N/A
9/30/2019	N/A	3	-27	-27	N/A
6/30/2019	N/A	4	-29	-29	N/A
3/31/2019	N/A	-7	-27	-27	N/A
12/31/2018	N/A	-38	-26	-26	N/A
9/30/2018	N/A	-48	-25	-25	N/A
6/30/2018	N/A	-46	-25	-25	N/A
3/31/2018	N/A	-28	-25	-25	N/A
12/31/2017	N/A	-16	-25	-25	N/A
9/30/2017	N/A	-10	-27	-27	N/A
6/30/2017	N/A	-19	N/A	-29	N/A
3/31/2017	N/A	-26	N/A	-29	N/A
12/31/2016	N/A	-29	N/A	-29	N/A
9/30/2016	N/A	-37	N/A	-27	N/A
6/30/2016	N/A	-32	N/A	-25	N/A
3/31/2016	N/A	-29	N/A	-24	N/A
12/31/2015	N/A	-25	N/A	-22	N/A
9/30/2015	N/A	-22	N/A	-20	N/A
6/30/2015	N/A	-33	N/A	-20	N/A
3/31/2015	N/A	-34	N/A	-17	N/A
12/31/2014	N/A	-35	N/A	-15	N/A
9/30/2014	N/A	-41	N/A	-14	N/A
6/30/2014	N/A	-29	N/A	-12	N/A
3/31/2014	N/A	-24	N/A	-13	N/A
12/31/2013	N/A	-24	N/A	-14	N/A
9/30/2013	N/A	-19	N/A	-15	N/A
6/30/2013	N/A	-20	N/A	-16	N/A
3/31/2013	N/A	-20	N/A	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Unzureichende Daten, um festzustellen, ob das prognostizierte Gewinnwachstum von CFRX über der Sparquote liegt (2.2%).

Ertrag vs. Markt: Unzureichende Daten, um festzustellen, ob die Gewinne von CFRX schneller wachsen werden als der Markt US

Hohe Wachstumserträge: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von CFRX in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von CFRX schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: CFRX wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von CFRX in 3 Jahren voraussichtlich hoch sein wird

ContraFect Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased to US$2.00

No longer forecast to breakeven

Price target decreased to US$13.00

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Recent updates

ContraFect Corporation Filed for Bankruptcy

ContraFect Corporation Announces Chief Executive Officer Changes

ContraFect Receives Determination Letter from the Nasdaq Hearings Advisor to Delist its Common Stock from the Nasdaq Capital Market

ContraFect Receives Non Compliance Notice from Nasdaq

Nasdaq Determines to Delist ContraFect's Common Stock from The Nasdaq Capital Market Due to Non-Compliance with Minimum Stockholders' Equity Requirement

ContraFect Corporation Presents Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company's Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-Neg Pathogens

ContraFect Announces Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq Determines to Deny ContraFect's Request for Continued Listing on the Nasdaq Capital Market

ContraFect Corporation Provides Update from the Futility Analysis of the Phase 3 DISRUPT Study of Exebacase

ContraFect Corporation Announces ANSM Approval of Clinical Trial Application for Exebacase in Prosthetic Joint Infections

Price target decreased to US$2.00

ContraFect Receives Non-Compliance Letter from Nasdaq

Contrafect Corporation Announces Resignation of Cara Cassino as Chief Medical Officer and Executive Vice President of Research and Development

Contrafect GAAP EPS of -$0.46 misses by $0.13

No longer forecast to breakeven

Contrafect Announces Independent Dsmb Recommends Exebacase Phase 3 Disrupt Study Be Stopped for Futility Following Interim Analysis

ContraFect sinks ~76% as data safety board recommends ending co's DISRUPT trial

ContraFect (NASDAQ:CFRX) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$13.00

ContraFect Corporation, Annual General Meeting, May 17, 2022

Price target decreased to US$13.00

Price target decreased to US$13.00

Forecast to breakeven in 2024

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

ContraFect: Non-Antibiotic Alternative That Could Disrupt The Antibiotic Market

We're Keeping An Eye On ContraFect's (NASDAQ:CFRX) Cash Burn Rate

ContraFect Corporation(NasdaqCM:CFRX) dropped from Russell 3000E Growth Index

Forecast to breakeven in 2024

Price target decreased to US$15.90

Is ContraFect (NASDAQ:CFRX) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

ContraFect Corporation Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook

Are Institutions Heavily Invested In ContraFect Corporation's (NASDAQ:CFRX) Shares?

New 90-day low: US$4.81

ContraFect Corporation Appoints Jane F. Barlow to its Board of Directors

New 90-day low: US$4.96

Is ContraFect (NASDAQ:CFRX) In A Good Position To Invest In Growth?

New 90-day low: US$5.09

New 90-day high: US$5.87

What Type Of Shareholders Make Up ContraFect Corporation's (NASDAQ:CFRX) Share Registry?

Contrafect EPS beats by $0.16

Analysts update estimates

ContraFect Corporation announced that it has received $3 million in funding from Pfizer Inc.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken